Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Net Margin (2016 - 2023)

Seres Therapeutics' Net Margin history spans 8 years, with the latest figure at 194795.31% for Q4 2023.

  • For Q4 2023, Net Margin fell 18773931.0% year-over-year to 194795.31%; the TTM value through Sep 2025 reached 3372.76%, up 9378057.0%, while the annual FY2023 figure was 60.48%, 356998.0% up from the prior year.
  • Net Margin for Q4 2023 was 194795.31% at Seres Therapeutics, down from 2206.13% in the prior quarter.
  • Across five years, Net Margin topped out at 480.66% in Q4 2020 and bottomed at 194795.31% in Q4 2023.
  • The 5-year median for Net Margin is 612.61% (2020), against an average of 11638.09%.
  • The largest YoY upside for Net Margin was 536041bps in 2023 against a maximum downside of -18773931bps in 2023.
  • A 5-year view of Net Margin shows it stood at 358.08% in 2019, then surged by 234bps to 480.66% in 2020, then plummeted by -243bps to 688.06% in 2021, then tumbled by -925bps to 7056.0% in 2022, then crashed by -2661bps to 194795.31% in 2023.
  • Per Business Quant, the three most recent readings for MCRB's Net Margin are 194795.31% (Q4 2023), 2206.13% (Q3 2023), and 36.81% (Q2 2023).